Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2018

Open Access 01-12-2018 | Research

Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance

Authors: Miyuki Morishita, Toshiaki Endo, Tsuyoshi Baba, Yoshika Kuno, Keiko Ikeda, Tamotsu Kiya, Hiroyuki Honnma, Tsuyoshi Saito

Published in: Journal of Ovarian Research | Issue 1/2018

Login to get access

Abstract

Background

Hyperandrogenism and insulin resistance may be related to the etiology of PCOS. Zucker fa/fa rats with polycystic ovary are obese, have insulin resistance without diabetes mellitus or hyperandrogenism and can be utilized as PCOS model rats without effects of hyperandrogenemia. PCOS patients are reported to have elevated levels of serum anti-Mullerian hormone (AMH), which has an inhibitory action on folliculogenesis, and low levels of serum adiponectin, which blocks apoptosis and induces biological effects in some tissues. Pioglitazone, an insulin sensitizer, is administered to PCOS patients with insulin resistance to induce ovulation but the mechanisms by which this occurs have not been elucidated.

Methods

We purchased 4-week-old female fatty Zucker fa/fa rats as well as lean Zucker +/+ rats for use as control rats with normal insulin sensitivity. The Zucker fa/fa rats were administered pioglitazone (2.5 mg/kg body weight/day) or a vehicle every day for 14 days in separate groups. The Zucker +/+ rats were also administered the vehicle. After 2 weeks of treatment, they were euthanized and we obtained serum samples and both ovaries and determined the body weight, ovarian weight, and serum AMH, adiponectin, testosterone, and androstenedione levels. We also examined ovarian histology to check follicle numbers by using hematoxylin-eosin staining, and the number of atretic follicles using Tdt-mediated dUTP nick end labeling (TUNEL) methods.

Results

The Zucker fa/fa rats used as PCO model rats and Pioglitazone treated PCO model rats were significantly heavier than the Zucker +/+ control rats (p < 0.05) at 15 day old. Pioglitazone treatment did not influence body weight or ovarian weight in either group. However, the total number of follicles was significantly larger in the PCO model rats than in the control rats (P < 0.05).
Although pioglitazone treatment appeared to decrease the total number of follicles in the PCO model rats, the decrease was not statistically significant. However, pioglitazone treatment significantly decreased the total number of atretic follicles and the rate of atreteic follicles in the PCO model rats (P < 0.05). The serum AMH level was significantly higher in the PCO model rats than in the control rats. Pioglitazone treatment significantly decreased the serum AMH level and significantly increased the serum adiponectin level in the PCO model rats (P < 0.05). Serum testosterone and androstenedione levels were quite low or undetectable in the 3 groups of rats, and were not influenced by pioglitazone treatment.

Conclusion

In this study, pioglitazone treatment reduced the serum AMH level and increased the serum adiponectin level in PCO model rats. These effects are related to reduction of the total number of atretic follicles and rate of atretic follicles. This proves that pioglitazone treatment improves healthy follicle growth in these PCO model rats with insulin resistance.
Literature
1.
Honnma H, Endo T, Kiya T, Shimizu A, Nagasawa K, Baba T, Fujimoto T, Henmi H, Kitajima Y, Manase K, Ishioka S, Ito E, Saito T. Remarkable features of ovarian morphology and reproductive hormones in insulin-resistant Zucker fatty (fa/fa) rats. Reprod Biol Endocrinol. 2010;8:73.CrossRefPubMedPubMedCentral
2.
Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23:205–15.CrossRefPubMed
3.
Kim CH, Jeon GH, Kim SR, Kim SH, Chae HD, Kang BM. Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertil Steril. 2010;94:236–41.CrossRefPubMed
4.
Du Q, Yang S, Wang YJ, Wu B, Zhao YY, Fan B. Thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials. Adv Ther. 2012;29:763–74.CrossRefPubMed
5.
Koo YA, Shin SY, Yoon BK, Choi D. Pioglitazone for teating polycystic ovary syndrome in non-obese women of reproductive age different clinical presentations. Gyneocl Endocrinol. 2007;23:461–7.CrossRef
6.
Ota H, Goto T, Yoshida T, Ohyama N. Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril. 2008;90:709–13.CrossRefPubMed
7.
Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P, Holcomb K, Chang P, Poretsky L. Direct thazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab. 2005;90:6099–105.CrossRefPubMed
8.
Xu Y, Wu Y, Huang Q. Comparison of the effect between pioglitazone and metformin in treating patients with PCOS: a meta-analysis. Arch Gynecol Obstet. 2017;296:661–77.CrossRefPubMedPubMedCentral
9.
Iwahashi H, Kuriyama H, Ouchi H, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T. Matsuzawa y: plasma cocentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–9.CrossRefPubMed
10.
Stefan N, Stumvoll M. Adiponectin-its role in metabolism and beyond. Horm Metab Res. 2002;34:469–74.CrossRefPubMed
11.
Matsubara M, Maruoka S, katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764–9.CrossRefPubMed
12.
Kazumi T, Kawaguchi A, Sakai K, Hiarano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care. 2002;25:971–6.CrossRefPubMed
13.
Arita Y, Kihar S, Ouchi NO, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an dipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.CrossRefPubMed
14.
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–5.CrossRefPubMed
15.
Lin LY, Lin CY, Su TC, Liau CS. Angiotensin II-induced apoptosis in human endothelial cell is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90. FEBS Lett. 2004;574:106–10.CrossRefPubMed
16.
Oana F, Takeda H, Hayakawa K, Matsuzawa A, Akahane S, Isaji M, Akahane M. Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin. Metabolism. 2005;54:995–1001.CrossRefPubMed
17.
Caminos JE, Nogueiras R, Gaytan F, Pineda R, Gonzalez CR, Barreiro ML, Castano JP, Malagon MM, Pinilla L, Toppari J, Dieguez C, Tena-Sempere M. Novel expression and direct effects of adiponectin in the rat testis. Endocrinology. 2008;149:3390–402.CrossRefPubMed
18.
Chabrolle C, Tosca L, Dupont J. Regulation of adiponectin and its receptors in rat ovary by human chorionic gonadogrophin treatment and potential involvement of adiponectin in granulosa cell steroidogenesis. Reproduction. 2007;133:719–31.CrossRefPubMed
19.
Chabrolle C, Jeanpierre E, Tosca L, Rame C, Dupont J. Effects of high levels of glucose on the steroidogenesis and the expression of adiponectin receptors in rat ovarian cells. Reprod Biol Endocrinol. 2008;6:11.CrossRefPubMedPubMedCentral
20.
Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol. 2008;284:38–45.CrossRefPubMed
21.
Pellatt L, Rice S, Mason HD. Anti-Mullerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010;139:825–33.CrossRefPubMed
22.
Marin Bivens CL, Olster DH. Abnormal estrous cyclicity and behavioral hyporesponsiveness to ovarian hormones in genetically obese Zucker female rats. Endocrinology. 1997;138:143–8.CrossRefPubMed
23.
Hamm ML, Bhat GK, Thompson WE, Mann DR. Folliculogenesis is impaired and granulosa cell apoptosis is increased in leptin-deficient mice. Biol Reprod. 2004;71:66–72.CrossRefPubMed
24.
Singh A, Bora P, Krishna A. Direct action of adiponectin ameliorates increased androgen synthesis and reduces insulin receptor expression in the polycystic ovary. Biochem Biophs Res Commun. 2017;488:509–15.CrossRef
25.
Comim FV, Hardy K, Franks S. Adiponectin and its receptors in the ovary: further evidence for a link between obesity and hyperandrogenism in polycystic ovary syndrome. PLoS One. 2013;8:e80416.CrossRefPubMedPubMedCentral
26.
Froment P, Gizard F, Staels B, Dupont J, Monget P. A role of PPARgamma in reproduction? Med Sci (Paris). 2005;21:507–11.
27.
Anastasiou OE, Canbay A, Fuhrer D, Reger-Tan S. Metabolic and androgen profile in underweight women with polycystic ovary syndrome. Arc Gynecol Obstet. 2017;296:363–71.CrossRef
28.
Doganay M, Ozyer SS, Var T, Tonguc E, Gun Eryilmaz O, Ozer I, Guzel AI. Associations between adipocyte fatty acid-binding protein and clinical parameters in polycystic ovary syndrome. Arc Gynecol Obstet. 2015;291:447–50.CrossRef
29.
Schoppee PD, Garmery JC, Veldhuis JD. Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Biol Reprod. 2002;66:190–8.CrossRefPubMed
30.
Carmiana E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, Lombrdi G, Lobo RA. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 2005;152:389–94.CrossRef
31.
Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchon R, Luque-Ramirez M, San Millan JL. Adiponectin and resistin in PCOS: a clinical biochemical and molecular genetic study. Hum Reprod. 2006;21:2257–65.CrossRefPubMed
32.
Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, Szymczak J, Bednarek-Tupikowska G, Demissie M. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol. 2008;24:378–84.CrossRefPubMed
33.
Campos DB, Palin MF, Bordignon V, Murphy BD. The beneficial adipokines in reproduction and fertility. Int J obes (Lond). 2008;32:223–31.CrossRef
34.
Singh A, Bora P, Krishna A. Systemic adiponectin treatment reverses polycystic ovary syndrome-like features in an animal model. Reprod Fertil Dev. 2017;10:1071/RD17255. [Epub ahead of Print]
Metadata
Title
Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance
Authors
Miyuki Morishita
Toshiaki Endo
Tsuyoshi Baba
Yoshika Kuno
Keiko Ikeda
Tamotsu Kiya
Hiroyuki Honnma
Tsuyoshi Saito
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2018
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-018-0395-y

Other articles of this Issue 1/2018

Journal of Ovarian Research 1/2018 Go to the issue

Case report

Rapidly growing juvenile granulosa cell tumor of the ovary arising in adult: a case report and review of the literature

Research

Diagnostic utility of CT in differentiating between ruptured ovarian corpus luteal cyst and ruptured ectopic pregnancy with hemorrhage

Case report

Neurofibroma involving obturator nerve mimicking an adnexal mass: a rare case report and PRISMA-driven systematic review

Research

Beneficial effects of curcumin and capsaicin on cyclophosphamide-induced premature ovarian failure in a rat model

Research

Is the aging human ovary still ticking?: Expression of clock-genes in luteinized granulosa cells of young and older women

Research

Fresh versus frozen embryo transfer for full-term singleton birth: a retrospective cohort study